Diocésio Alves Pinto de Andrade

Learn More
PURPOSE OF REVIEW After multimodal treatment, 50-60% of patients with locally advanced squamous cell carcinoma of the head and neck will present locoregional and/or distant relapse within 2 years. This article will review chemotherapy and/or targeted agents as treatment options for patients who progress after platinum-based chemotherapy. RECENT FINDINGS(More)
PURPOSE To perform a meta-analysis addressing evaluation bias in local radiologic assessment (LRA) of lesions when compared with independent radiologic review (IRR) in randomized controlled trials (RCTs) testing chemotherapy for metastatic colorectal cancer (CRC). MATERIALS AND METHODS MEDLINE, EMBASE, ClinicalTrials.gov, the Cochrane Library, and Web(More)
Bevacizumab-containing treatment is one of the approved first-line options for the management of metastatic colorectal cancer (CRC). Carcino-embryonic antigen (CEA) is a reasonable tumour marker for monitoring the efficacy of treatment. We report here a case of a 58-year-old male patient with metastatic CRC. He received first-line chemotherapy consisting of(More)
  • 1